Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tharimmune ( (THAR) ) just unveiled an announcement.
On January 20, 2026, Tharimmune, Inc. entered into an underwriting agreement with Clear Street LLC for a registered direct offering to a single institutional investor, comprising 1.8 million common shares at $2.92 per share and pre-funded warrants to purchase up to 17 million additional shares at a marginally discounted price. The transaction, which closed on January 22, 2026, raised approximately $55 million in gross proceeds, with the capital earmarked primarily to expand and develop Tharimmune’s Canton-centric digital asset treasury strategy and to bolster general working capital, reinforcing the company’s push deeper into institutional blockchain infrastructure while providing additional financial flexibility alongside its ongoing at-the-market equity program.
More about Tharimmune
Tharimmune, Inc. (NASDAQ: THAR) operates a dual business model, combining a differentiated digital asset treasury strategy centered on the Canton Network with clinical-stage biotech research and development. It positions itself as the first publicly traded company to leverage Canton Coin in support of the Canton Network’s efforts to digitize traditional financial markets, targeting institutional blockchain adoption while maintaining exposure to biopharmaceutical innovation.
Average Trading Volume: 1,423,703
Technical Sentiment Signal: Hold
Current Market Cap: $109.2M
For an in-depth examination of THAR stock, go to TipRanks’ Overview page.